SynKIR-110

DB17365InvestigationalCell transplant therapies

SynKIR-110 are autologous T cells genetically engineered to express an anti-mesothelin killer immunoglobulin-like receptor-chimeric antigen receptor (KIR-CAR).

Mechanism: Pharmacologically active on Mesothelin
Curator reviewed
Also known as: SynKIR-meso · SynKIR-meso CAR-T cells

Resolves to

Targets

Q13421MSLN

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with SynKIR-110, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account